Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

NCT01055028 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT01055028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01055028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2010
Completion date
June 24, 2016
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcomas, soft tissue sarcoma